Short answer
AbbVie Inc (ABBV) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $17.4B (up 10.3% year over year) with net income of $4.2B.
Q3 2026 key financials · XBRL
- Revenue
- $17.4B
- +10.3% YoY · +2.4% QoQ
- Net income
- $4.2B
- +2167.7% YoY · +16.7% QoQ
- Operating margin
- 36.0%
- EPS (diluted)
- $2.37
- +2270.0% YoY · +16.7% QoQ
Source: XBRL data from the AbbVie Inc (ABBV) Q3 2026 10-Q on SEC EDGAR. USD.
AbbVie Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $17,404M, up 10.3% YoY from $15,776M
- Gross margin $13,119M, 75.4% vs 66.4% YoY
- Best performer: Skyrizi revenue $5,776M, up 22.7%; worst: Humira, down 31.2%
- Operating cash flow $14,871M, up from $13,812M; acquisitions used $10.6B
- Headwinds: biosimilar competition, drug pricing reform, tariffs and global macroeconomic uncertainty
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AbbVie Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.